Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Hemophilia B, or factor IX deficiency, is an X-linked recessive disorder occurring in about 1 in 25,000 males. Affected individuals are at risk for spontaneous bleeding into many organs; treatment mainly consists of the transfusion of clotting factor concentrates prepared from human blood or recombinant sources after bleeding has started. Small- and large-animal models have been developed and/or characterized that closely mimic the human disease state. As a preclinical model for gene therapy, recombinant adeno-associated viral vectors containing the human or canine factor IX cDNAs were infused into the livers of murine and canine models of hemophilia B, respectively. There was no associated toxicity with infusion in either animal model. Constitutive expression of factor IX was observed, which resulted in the correction of the bleeding disorder over a period of over 17 months in mice. Mice with a steady-state concentration of 25% of the normal human level of factor IX had normal coagulation. In hemophilic dogs, a dose of rAAV that was approximately 1/10 per body weight that given to mice resulted in 1% of normal canine factor IX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect for at least 8 months.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [2]
In the citing paper
“Capsid-specific T cell responses to AAV-based therapies were not predicted from proof-of-concept studies in animal models but were identified in human studies.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [2]
Citations
Cites
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Samulski, R. J., Chang, L. S., & Shenk, T. (1989) · Journal of Virology · doi:10.1128/jvi.63.9.3822-3828.1989 · Cited by 743
A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells
Zolotukhin, S., Potter, M., Hauswirth, W. W., Guy, J., & Muzyczka, N. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4646-4654.1996 · Cited by 609
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593
Dai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., & Verma, I. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1401 · Cited by 591
Snyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Self-citationHerzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474
Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice
Smith, T. A. G., Mehaffey, M. G., Kayda, D. B., Saunders, J. M., Yei, S., Trapnell, B. C., McClelland, A., & Kaleko, M. (1993) · Nature Genetics · doi:10.1038/ng1293-397 · Cited by 335
Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., et al. (1998) · Blood · doi:10.1182/blood.v92.1.68.413k23_68_75 · Cited by 304
In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs
Kay, M. A., Rothenberg, S., Landen, C. N., Bellinger, D. A., Leland, F., Toman, C., Finegold, M., Thompson, A. R., Read, M. S., Brinkhous, K. M., et al. (1993) · Science · doi:10.1126/science.8211118 · Cited by 304
Self-citation
Research works printed but not linked: 2
- Brinkhous, K.M. et al. Pharmacokinetics and pharmacodynamics of a B-domain deleted recombinant factor VIII derivative, r-VIII SQ, in canine hemophilia. Thromb. Haemost. 69, 852 (1993 ).
- Brinkhous, K.M., Landen, C.N. & Read, M.S. Evaluation of sensitivity of whole blood clotting time (WBCT), partial thromboplastin time (PTT), and F.IX one-stage bioassay tests with low plasma F.IX levels observed with transfusion or gene therapy in canine hemophilia B. Blood 82, suppl 1 :592a (1993).
Cited by
Items 201–300 of 429
Role of Molecular Genetics in Hemophilia: From Diagnosis to Therapy
Jayandharan, G. R., Srivastava, A., & Srivastava, A. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0031-1300953 · Cited by 43
Immune Implications of Gene Therapy for Hemophilia
Herzog, R., & Dobrzynski, E. (2004) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2004-825635 · Cited by 44
Fields, P., Armstrong, E., Hagstrom, J. N., Arruda, V. R., Murphy, M., Farrell, J. P., High, K. A., & Herzog, R. W. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301409 · Cited by 43
Sun, M.-S., Pan, C.-J., Shieh, J.-J., Ghosh, A., Chen, L.-Y., Mansfield, B. C., Ward, J. M., Byrne, B. J., & Chou, J. Y. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.18.2155 · Cited by 42
Therapeutic Effects of Hepatocyte Transplantation on Hemophilia B
Tatsumi, K., Ohashi, K., Shima, M., Nakajima, Y., Okano, T., & Yoshioka, A. (2008) · Transplantation · doi:10.1097/tp.0b013e31817b9160 · Cited by 41
Haematopoietic stem cell transplantation and gene therapy in the fetus: ready for clinical use?
Surbek, D., Holzgreve, W., & Nicolaides, K. H. (2001) · Human Reproduction Update · doi:10.1093/humupd/7.1.085 · Cited by 41
Couto, L. B., Parker, A. E., & Gordon, J. W. (2004) · Human Gene Therapy · doi:10.1089/104303404322886138 · Cited by 41
Su, W., Kang, J., Sopher, B., Gillespie, J., Aloi, M. S., Odom, G. L., Hopkins, S., Case, A., Wang, D. B., Chamberlain, J. S., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13081 · Cited by 32
Dual Vectors Expressing Murine Factor VIII Result in Sustained Correction of Hemophilia A Mice
Mah, C., Sarkar, R., Zolotukhin, I., Schleissing, M., Xiao, X., Kazazian, H. H., & Byrne, B. J. (2003) · Human Gene Therapy · doi:10.1089/104303403321070838 · Cited by 36
Treatment of hemophilia B in mice with nonautologous somatic gene therapeutics
Raamsdonk, J. M. V., Ross, C. J., Potter, M., Kurachi, S., Kurachi, K., Stafford, D. W., & Chang, P. L. (2002) · Journal of Laboratory and Clinical Medicine · doi:10.1067/mlc.2002.120649 · Cited by 40
Self-citationHortelano, G., Wang, L., Xu, N., & Ofosu, F. A. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00492.x · Cited by 40
The promise of gene therapy in gastrointestinal and liver diseases
Prìeto, J., Herráiz, M., Sangro, B., Qian, C., Mazzolini, G., Melero, I., & Ruiz, J. (2003) · Gut · doi:10.1136/gut.52.suppl_2.ii49 · Cited by 40
Modeling Pulmonary Disease Pathways Using Recombinant Adeno-Associated Virus 6.2
Strobel, B., Duechs, M. J., Schmid, R., Stierstorfer, B., Bucher, H., Quast, K., Stiller, D., Hildebrandt, T., Mennerich, D., Gantner, F., et al. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0338ma · Cited by 39
Cheng, H., Wolfe, S. H., Valencia, V., Qian, K., Shen, L., Phillips, M. I., Chang, L., & Zhang, Y. C. (2007) · Journal of Biomedical Science · doi:10.1007/s11373-007-9159-1 · Cited by 39
Eslami, M. H., Gangadharan, S. P., Sui, X., Rhynhart, K. K., Snyder, R. O., & Conte, M. S. (2000) · Journal of Vascular Surgery · doi:10.1067/mva2000.106951 · Cited by 39
Self-citationTranslational Data from AAV-Mediated Gene Therapy of Hemophilia B in Dogs
Nichols, T. C., Whitford, M. H., Arruda, V. R., Stedman, H. H., Kay, M. A., & High, K. A. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/hum.2014.153 · Cited by 38
Self-citationGene therapy for hemophilia: an imperative to succeed
Hough, C. A., & Lillicrap, D. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01401.x · Cited by 38
Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector
Sun, B., Chen, Y.-T., Bird, A., Amalfitano, A., & Koeberl, D. D. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00055-2 · Cited by 38
How not to be seen: immune-evasion strategies in gene therapy
Zaldumbide, A., & Hoeben, R. C. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303082 · Cited by 38
Ye, X., Loeb, K. R., Stafford, D. W., Thompson, A. R., & Miao, C. H. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00024.x · Cited by 38
Self-citationGene therapy of pain: emerging strategies and future directions
Pohl, M., & Bráz, J. M. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01304-8 · Cited by 37
Correction of a murine model of von Willebrand disease by gene transfer
Pergolizzi, R. G., Jin, G., Chan, D., Pierre-Destine, L., Bussel, J. B., Ferris, B., Leopold, P. L., & Crystal, R. G. (2006) · Blood · doi:10.1182/blood-2005-06-2330 · Cited by 37
Preclinical and clinical gene therapy for haemophilia
Chuah, M., Collen, D., & VandenDriessche, T. (2004) · Haemophilia · doi:10.1111/j.1365-2516.2004.00984.x · Cited by 36
Gene therapy: reality or myth for the global bleeding disorders community?
Kelley, K., Verma, I. M., & Pierce, G. F. (2002) · Haemophilia · doi:10.1046/j.1365-2516.2002.00646.x · Cited by 36
In Vivo Selection of Hepatocytes Transduced with Adeno-Associated Viral Vectors
Chen, S. J., Tazelaar, J., Moscioni, A. D., & Wilson, J. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0065 · Cited by 36
Recent Progress in Gene Therapy for Hemophilia
Chuah, M., Nair, N., & VandenDriessche, T. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.088 · Cited by 34
Cao, O., Armstrong, E., Schlachterman, A., Wang, L., Okita, D. K., Conti-Fine, B., High, K. A., & Herzog, R. W. (2006) · Blood · doi:10.1182/blood-2005-11-4668 · Cited by 34
Muscle‐directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors
Wang, L., Louboutin, J. P., Bell, P. L., Greig, J. A., LI, Y., WU, D., & Wilson, J. M. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04491.x · Cited by 32
Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.116 · Cited by 32
Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene
Sabatino, D. E., Armstrong, E., Edmonson, S., Liu, Y.-L., Pleimes, M., Schuettrumpf, J., Fitzgerald, J., Herzog, R. W., Arruda, V. R., & High, K. A. (2004) · Blood · doi:10.1182/blood-2004-03-1028 · Cited by 32
Ribozyme Gene Therapy for Autosomal Dominant Retinal Disease
Hauswirth, W. W., LaVail, M. M., Flannery, J. G., & Lewin, A. S. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.022 · Cited by 32
Sun, B., Chen, Y.-T., Bird, A., Xu, F., Hou, Y.-X., Amalfitano, A., & Koeberl, D. D. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00022-4 · Cited by 32
Herzog, R. W., & High, K. A. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615877 · Cited by 32
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
Self-citationAAV Biology, Infectivity and Therapeutic Use from Bench to Clinic
Vance, M. A., Mitchell, A., & Samulski, R. J. (2015) · Gene Therapy - Principles and Challenges · doi:10.5772/61988 · Cited by 21
The Hopes and Fears of In Utero Gene Therapy for Genetic Disease—A Review
Coutelle, C., Themis, M., Waddington, S. N., Gregory, L. G., Nivsarkar, M. S., Buckley, S. M. K., Cook, H. T., Rodeck, C. H., Peebles, D., & David, A. L. (2003) · Placenta · doi:10.1016/s0143-4004(03)00140-1 · Cited by 31
Flageul, M., Aubert, D., Pichard, V., Nguyen, T. H., Nowrouzi, A., Schmidt, M., & Ferry, N. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1343 · Cited by 31
Molas, M., Bartrons, R., & Perales, J. C. (2002) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00276-3 · Cited by 31
Fetal gene therapy: Opportunities and risks
Wagner, A. M., Schoeberlein, A., & Surbek, D. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.011 · Cited by 30
In vivo Gene Transfer to Healthy and Diabetic Canine Pancreas
Ayuso, E., Chillón, M., García, F., Agudo, J., Andaluz, A., Carretero, A., Monfar, M., Moya, M., Montané, J., Otaegui, P. J., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.017 · Cited by 30
Gene Therapy - Principles and Challenges
Hashad, D. I. (2015) · InTech eBooks · doi:10.5772/59824 · Cited by 30
Liver depot gene therapy for Pompe disease
Kishnani, P. S., & Koeberl, D. D. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.02 · Cited by 30
Expression of Coagulation Factor IX in a Haematopoietic Cell Line
Rodriguez, M., Enjolras, N., Plantier, J., Réa, M., Leboeuf, M., Uzan, G., Bordet, J., & Négrier, C. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613013 · Cited by 30
Epstein‐Barr Virus Vectors Provide Prolonged Robust Factor IX Expression in Mice
Sclimenti, C. R., Neviaser, A. S., Baba, E. J., Meuse, L., Kay, M. A., & Calos, M. P. (2003) · Biotechnology Progress · doi:10.1021/bp0200907 · Cited by 29
Self-citationOgura, T., Mizukami, H., Mimuro, J., Madoiwa, S., Okada, T., Matsushita, T., Urabe, M., Kume, A., Hamada, H., Yoshikawa, H., et al. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.916 · Cited by 28
Li, H., Li, X., Lam, K. S. L., Tam, S., Xiao, W., & Xu, R. (2008) · Journal of Biomedical Science · doi:10.1007/s11373-008-9233-3 · Cited by 27
Plastic Surgical Delivery Systems for Targeted Gene Therapy
Ghali, S., Dempsey, M., Jones, D. M., Grogan, R. H., Butler, P. E. M., & Gurtner, G. C. (2008) · Annals of Plastic Surgery · doi:10.1097/sap.0b013e31806917b0 · Cited by 27
Graham, T., McIntosh, J., Work, L. M., Nathwani, A. C., & Baker, A. H. (2008) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-6-9 · Cited by 27
Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
High, K. A. (2003) · PubMed · Cited by 27
Gene therapy of the hemophilias
Lozier, J. N. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.07.005 · Cited by 27
Gene therapy: progress and challenges.
Meyer, F., & Finer, M. H. (2001) · PubMed · Cited by 27
Koeberl, D. D., Bonham, L., Halbert, C. L., Allen, J. M., Birkebak, T. A., & Miller, A. D. (1999) · Human Gene Therapy · doi:10.1089/10430349950017121 · Cited by 27
CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver
Kaltenbacher, T., Löprich, J., Maresch, R., Weber, J., Müller, S., Oellinger, R., Groß, N., Griger, J., Krätzig, N. D. A., Avramopoulos, P., et al. (2022) · Nature Protocols · doi:10.1038/s41596-021-00677-0 · Cited by 26
Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice
Wen, J., Xu, N., Li, A., Bourgeois, J. M., Ofosu, F. A., & Hortelano, G. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1098 · Cited by 26
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
Haemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 26
Candidate Diseases for Prenatal Gene Therapy
David, A. L., & Waddington, S. N. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-873-3_2 · Cited by 25
Kitajima, K., Marchadier, D. H. L., Burstein, H., & Rader, D. J. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.07.009 · Cited by 26
Gene therapy of Parkinson’s disease using Adeno-Associated Virus (AAV) vectors
OZAWA, K., Fan, D. S., Shen, Y., Muramatsu, S., Fujimoto, K., Ikeguchi, K., Ogawa, M., Urabe, M., Kume, A., & Nakano, I. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6284-2_15 · Cited by 26
Flotte, T. R. (2013) · Molecular Therapy · doi:10.1038/mt.2013.226 · Cited by 25
Turnbull, A. E., Skulimowski, A., Smythe, J. A., & Alexander, I. E. (2000) · Human Gene Therapy · doi:10.1089/10430340050015815 · Cited by 25
Linden, R. M., & Woo, S. L. C. (1999) · Nature Medicine · doi:10.1038/4698 · Cited by 25
Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B
Nichols, T. C., Raymer, R. A., Franck, H. W. G., Merricks, E. P., Bellinger, D. A., DeFriess, N., Margaritis, P., Arruda, V. R., Kay, M. A., & High, K. A. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02255.x · Cited by 24
Self-citationJakob, M., Mühle, C., Park, J., Weiß, S., Waddington, S. N., & Schneider, H. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.718 · Cited by 24
Absence of Circulating Factor IX Antigen in Hemophilia B Dogs of the UNC-Chapel Hill Colony
Herzog, R. W., Arrada, V., Fisher, T. R., Read, M. S., Nichols, T. C., & High, K. A. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614021 · Cited by 24
Self-citationOhashi, K., Tatsum, K., Utoh, R., Takagi, S., Shima, M., & Okano, T. (2010) · Cell Transplantation · doi:10.3727/096368910x508924 · Cited by 23
Pharmacokinetics of Plasmid DNA‐Based Non‐viral Gene Medicine
Nishikawa, M., Takakura, Y., & Hashida, M. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)53003-7 · Cited by 23
Long‐term real‐time monitoring of adeno‐associated virus‐mediated gene expression in the rat retina
Rolling, F., Shen, W., Barnett, N. L., Tabarias, H. A., Kanagasingam, Y., Constable, I. J., & Rakoczy, P. E. (2000) · Clinical and Experimental Ophthalmology · doi:10.1046/j.1442-9071.2000.00341.x · Cited by 23
The Potential for Gene Therapy in the Treatment of Autoimmune Disease
Tarner, I. H., & Fathman, C. G. (2002) · Clinical Immunology · doi:10.1006/clim.2002.5235 · Cited by 23
Ho, P. P.-K., Lahey, L. J., Mourkioti, F., Kraft, P. E., Filareto, A., Brandt, M., Magnusson, K. E. G., Finn, E. E., Chamberlain, J. S., Robinson, W. H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808648115 · Cited by 22
Ultrasound-targeted hepatic delivery of factor IX in hemophiliac mice
Anderson, C. D., Moisyadi, S., Avelar, A., Walton, C. B., & Shohet, R. V. (2016) · Gene Therapy · doi:10.1038/gt.2016.23 · Cited by 22
A Novel Gene Expression System: Non‐Viral Gene Transfer for Hemophilia as Model Systems
Miao, C. H. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)54007-0 · Cited by 22
Self-citationAdeno-Associated Virus —Mediated Gene Transfer for Hemophilia B
High, K. A. (2002) · International Journal of Hematology · doi:10.1007/bf02982689 · Cited by 22
Chaanine, A. H., Kalman, J., & Hajjar, R. J. (2010) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2010.09.009 · Cited by 21
Update on gene therapy for hereditary hematological disorders
Herzog, R. W., & Arruda, V. R. (2003) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.2.215 · Cited by 20
Roy‐Chowdhury, J., & Schilsky, M. L. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.017 · Cited by 20
Perioperative Management of Hemophilia Patients
Lowell, A. E., Calgi, M. P., Caruso, J. J., Man, L. M.-W., & McNeil, J. S. (2024) · Current anesthesiology reports · doi:10.1007/s40140-024-00635-y · Cited by 19
Ohashi, K., Nakai, H., Couto, L. B., & Kay, M. A. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.299 · Cited by 19
Self-citationApolipoprotein A-V gene therapy for disease prevention/treatment: a critical analysis
Trudy, M., Vineeta, S., & Robert, O. (2016) · The Journal of Biomedical Research · doi:10.7555/jbr.30.20150059 · Cited by 18
Perinatal stem-cell and gene therapy for hemoglobinopathies
Surbek, D., Schoeberlein, A., & Wagner, A. M. (2008) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2008.03.002 · Cited by 18
Gene Therapy for Hemophilia: The Clot Thickens
High, K. A. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2541 · Cited by 18
DIMICHELE, D. M., Chuansumrit, A., London, A. J., Thompson, A. R., COOPER, C. G., Killian, R., Ross, L. F., Lillicrap, D., & Kimmelman, J. (2006) · Haemophilia · doi:10.1111/j.1365-2516.2006.01258.x · Cited by 18
Self-citationTargets for gene therapy of vein grafts
Newby, A. C., & Baker, A. H. (1999) · Current Opinion in Cardiology · doi:10.1097/00001573-199911000-00007 · Cited by 18
Gene Therapy for Hereditary Hematological Disorders
Herzog, R. W., & Hagstrom, J. N. (2001) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200101020-00006 · Cited by 18
Can genes transduced by adeno-associated virus vectors elicit or evade an immune response?
Wang, C.-H., Liu, D.-W., Tsao, Y.-P., Xiao, X., & Chen, S.-L. (2003) · Archives of Virology · doi:10.1007/s00705-003-0241-3 · Cited by 18
Pasi, J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03225.x · Cited by 18
Puppi, J., Guillonneau, C., Pichard, V., Bellodi‐Privato, M., Cuturi, M. C., Anegón, I., & Ferry, N. (2004) · Journal of Hepatology · doi:10.1016/s0168-8278(04)00172-2 · Cited by 18
Gene therapy for hemophilia? Yes
Négrier, C. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00934.x · Cited by 18
Gene therapy: therapeutic applications and relevance to pathology
Both, G. W., Alexander, I. E., Fletcher, S., Nicolson, T. J., Rasko, J. E. J., Wilton, S. D., & Symonds, G. P. (2011) · Pathology · doi:10.1097/pat.0b013e32834b1dad · Cited by 17
Adeno-associated virus-mediated gene transfer to the neonatal brain
Li, J., & Daly, T. M. (2002) · Methods · doi:10.1016/s1046-2023(02)00224-4 · Cited by 17
Adeno-associated viral delivery of a metabolically regulated insulin transgene to hepatocytes
Kozlowski, M., Olson, D. E., Rubin, J. E., Lyszkowicz, D., Campbell, A. G., & Thulé, P. M. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.04.011 · Cited by 17
Aubert, D., Pichard, V., Durand, S., Moullier, P., & Ferry, N. (2003) · Human Gene Therapy · doi:10.1089/104303403321467234 · Cited by 17
Duan, D., Yue, Y., Yan, Z., & Engelhardt, J. F. (2003) · Viral Vectors for Gene Therapy · doi:10.1385/1-59259-304-6:287 · Cited by 16
Chng, K., Larsen, S. R., Zhou, S., Wright, J. F., Martiniello‐Wilks, R., & Rasko, J. E. J. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.990 · Cited by 16
Prospects for fetal gene therapy
Yang, E. Y., Flake, A. W., & Adzick, N. S. (1999) · Seminars in Perinatology · doi:10.1016/s0146-0005(99)80031-7 · Cited by 16
Advances in Overcoming Immune Responses following Hemophilia Gene Therapy
H. Miao, C. (2012) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-007 · Cited by 15
Self-citationGene therapy – are we ready now?
Kaczmarek, R. (2022) · Haemophilia · doi:10.1111/hae.14530 · Cited by 15
Gene therapy for haemophilia: the end of a ‘royal pathology’ in the third millennium?
Liras, A. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00554.x · Cited by 15
Genetic analysis of the antibody response to AAV2 and factor IX
Zhang, H., High, K. A., Wu, Q., Yang, P., Schlachterman, A., Yu, S., Yi, N., Hsu, H., & Mountz, J. D. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.02.014 · Cited by 15
Gene therapy for treatment of inherited haematological disorders
Herzog, R. W., Cao, O., Hagstrom, J. N., & Wang, L. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.5.509 · Cited by 15
Metadata
- Authors
- Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., Read, M. S., Bellinger, D. A., Brinkhous, K. M., & Kay, M. A.
- Affiliations
- University of Washington (US)
- Stanford Medicine (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Medicine
- Published
- 1999-01
- Volume
- 5
- Issue
- 1
- Pages
- 64-70
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- DOI
- 10.1038/4751
- OpenAlex
- W1588659566
- Cited by
- 409
- References
- 30
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2022: 4 · 2021: 1 · 2020: 5 · 2019: 5 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 6 · 2014: 5 · 2013: 8 · 2012: 12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hl001648-50)
- National Heart, Lung, and Blood Institute (HL 53682, R01HL053682, HL-01648)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, adeno-associated virus vectors, gene therapy, canine model, mouse model, liver gene transfer, coagulation correction, X-linked bleeding disorder, vector toxicity
- MeSH terms
- Dependovirus, Animals, Antibodies, Bleeding Time, Cell Transformation, Viral, Hemophilia B, Disease Models, Animal, Dogs, Factor IX, Genetic Vectors, Humans, Liver, Mice, Inbred C57BL, Recombination, Genetic, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.